Safe delivery of CRISPR/Cas endonucleases remains one of the major barriers to the widespread application of in vivo genome editing including the anticipatory treatment of monogenic retinal diseases. We previously reported the utility of adeno-associated virus (AAV)-mediated CRISPR/Cas genome editing in the retina; however, with this type of viral delivery system, active endonucleases will remain in the retina for an extended period, making genotoxicity a significant consideration in clinical applications. To address this issue, we have designed a self-destructing "kamikaze" CRISPR/Cas system that disrupts the Cas enzyme itself following expression. Four guide RNAs (sgRNAs) were designed to target Streptococcus pyogenes Cas9 (SpCas9), after in situ validation, the selected sgRNAs were cloned into a dual AAV vector . One construct was used to deliver SpCas9 and the other delivered sgRNAs directed against SpCas9 and the target locus LacZ/SpCas9 targeting CRISPR/Cas) in transfected retina of Thy1-YFP transgenic mice. In conclusion, our data suggest that a self-destructive "kamikaze" CRISPR/Cas system can be used as a robust tool for refined genome editing in the retina, without compromising on-target efficiency.
INTRODUCTION
Inherited retinal diseases are disabling disorders of visual function and have affected millions of people worldwide. With the development of next-generation sequencing and better molecular diagnostic techniques, numerous genetic variants across many loci have been definitively associated with inherited retinal diseases. 1, 2 Despite this increase in our understanding of genetic aetiology and potential therapeutic targets, there remains no effective treatment for the majority of inherited retinal diseases. 3 Although significant progress in gene therapy have been achieved over the last two decades, a sustained, safe and effective ocular gene therapy for hereditary retinal diseases is not readily available for all conditions. 4, 5 Genome editing techniques, in particular the recent advances in CRISPR/Cas technology, has renewed excitement in ocular gene-based therapy. 6 The CRISPR/Cas system has evolved in archaea and bacteria as an adaptive defense against viral intrusion and has manipulated to allow efficient editing of mammalian nuclear genomes. 7 CRISPR/Cas-based technology has proven a robust means for in vitro correction of genetic mutations in mammalian cells and is particularly attractive for treating inherited retinal diseases. 3 A number of in vivo studies in various animal models have yielded promising results opening the prospect for preemptive therapy for well-characterised monogenic ocular diseases. Bakondi et al . 8 and Latella et al. 9 report successful ablation of the mutated rhodopsin gene prevented retinal degeneration in rodent models of severe autosomal dominant retinitis pigmentosa following electroporation of the CRISPR/Cas system into the retina. We were able to achieve high efficiency of genome editing in mouse retina using a dual AAV2-mediated CRISPR/Cas system. 10 More recently, Yu et al. 11 further demonstrated that CRISPR/Cas-mediated disruption of a neural retina-specific leucine zipper protein ( NRL ) significantly improved rod survival and preserved cone function in a murine model of retinal degeneration. Despite these promising applications in inherited retinal diseases, potentially deleterious off-target effects of CRISPR/Cas must be addressed, and it is well appreciated that prolonged over-expression of CRISPR/Cas endonucleases could result in elevated off-target cleavage, 12, 13 or potentially trigger cellular immune responses, 14 thereby presenting important safety concern for clinical applications.
To address the potential for deleterious effects of CRISPR/Cas over-expression, we have designed a self-destructive "kamikaze" CRISPR/Cas system that disrupts the CRISPR/Cas gene after active protein expression ( Figure 1 ). To determine the efficacy of in vivo genome editing by our "kamikaze" CRISPR/Cas construct, a SpCas9 targeting sgRNA module, together with a yellow fluorescent protein ( YFP ) targeting sgRNA, were packaged into a dual AAV2 vector system for intravitreal delivery in Thy1-YFP transgenic mice. Overall, our data demonstrates the feasibility of a self-destructive CRISPR/Cas system as a safe and robust tool for refined genome editing in the retina. digested pX551 plasmid was used as a positive control. Four SpCas9 sgRNAs were then cloned into a pX552-CMV-GFP plasmid (modified from Addgene #60958, by replacing the hSyn promoter with a CMV promoter) at the SapI restriction site for in vitro validation. Subsequently, the selected SpCas9 sgRNA (SpCas9 sgRNA4) was sub-cloned into a AAV package plasmid (pX552-hsyn-mCherry-YFP sgRNA2, sgRNA6 or pX552-LacZ sgRNA) at the MluI (catalog no.
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R3198; New England Biolabs) restriction site to generate YFP or LacZ targeting kamikaze CRISPR/Cas construct. For in vitro validation, pX551-CMV-SpCas9 plasmid was modified from pX551 plasmid by replacing the MeCP2 promoter with a CMV promoter.
Cell culture and transfection
Stable YFP expressing HEK293A cells were generated using a lentivirus as previously described. 10 
AAV production
Recombinant AAV2 viruses were produced in HEK293D cells (kindly provided by Ian Alexander,
Children's Medical Research Institute, Westmead, NSW, Australia) packaging either pX551 plasmid, containing SpCas9, or pX552-mCherry plasmid with the respective sgRNAs (spCas9, YFP or LacZ sgRNA), pseudoserotyped with the AAV2 capsid (pXX2), and purified using a AAV2pro
Purification Kit (catalog no. 6232; Clontech Laboratories, Mountain View, CA, USA) as previously described. 10, 15, 16 Viral titer was determined by real-time quantitative PCR using a Fast SYBR Green
Master Mix (catalog no. 4385612; Life Technologies Australia) with the pX551 or pX552 forward and reverse primers (Supplementary Table 1) .
Intravitreal Injection
For our in vivo time course analysis, a total of 76 C57BL/6 adult mice, aged between 12 and 14 weeks were randomly separated into two groups, to receive either AAV2-SpCas9+AAV2-YFP Mice were anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and xylazine (10 mg/kg). 15 Intravitreal injection was performed under a surgical microscope. After a small puncture was made through the conjunctiva and sclera using a 30-gauge needle, a hand-pulled glass micropipette connected to a 10 μL Hamilton syringe (Bio-Strategy, Broadmeadows, VIC, Australia) was inserted into the vitreous. A total of 1 μL dual-viral suspension (AAV2-SpCas9: 2.5x10 9 vector genomes vg/μL with AAV2-YFP sgRNA: 2.5x10 9 vg/μL, AAV2-SpCas9 sgRNA/YFP-sgRNA:
each mouse using a UMP3-2 Ultra Micro Pump (World Precision Instruments, Sarasota, FL, USA) at a rate of 200 nL/s. Any issues with the injection, including backflow upon removal of the needle, hemorrhaging of the external or internal vessels, retinal detachment were recorded and eyes were excluded from the study.
Electroretinography (ERG) and Optical Coherence Tomography ( OCT )
At 8 weeks following injection, mice underwent overnight dark-adaptation (~12 hours), followed by electroretinography assessment under fully dark-adapted conditions. Details for functional assessment have been outlined previously, 17 with the exception that the reference chloride silver electrode was placed around the outside of the eye. ERG analysis was as previously described 17 and returned the photoreceptor (a-wave), bipolar cell (b-wave), and ganglion cell dominated (scotopic threshold response, STR) components of the waveform. Group data are given as mean (± standard error of the mean).
Following ERG recordings, retinal images were obtained using a spectral domain-OCT (Bioptigen, Inc., Morrisville, NC, USA). Mice were positioned to capture Optic Nerve Head (ONH) centred 1.4 mm-wide horizontal B-scans (consisting of 1000 A-scans). ImageJ software (https://imagej.nih.gov/ij/) was used in a masked fashion to quantify total retinal thickness (from the inner limiting to Bruch's membrane), retinal nerve fibre layer thickness (from the inner limiting membrane to the inner aspect of the inner plexiform layer) and outer retinal thickness (from Bruch's membrane to the outer plexiform layer) in each eye.
Retinal flat-mount, imaging and counting
Eyes were removed, fixed in ice-cold 4% paraformaldehyde for 1 hour and dissected under a dissecting microscope. After removing the cornea, iris and lens, four equally spaced radial relaxing incisions, extending two thirds of the way from the retinal periphery to the ONH, were made. The sclera and choroid were then removed along with residual vitreous and hyaloid vessels, leaving only the retina. The fully dissected retina was stained with NucBlue™ Live ReadyProbes™ Reagent (catalog no. R37605; Life Technologies Australia) as a nuclear counterstain. Retinal images were captured by a fluorescence microscope (Zeiss Axio Imager Microscope; Carl-Zeiss-Strasse, Oberkochen, Germany) equipped with a charge-coupled digital camera (Axiocam MRm, Zeiss) and image acquisition software (ZEN2, Zeiss) as previously described. 10 The efficiency of YFP disruption was quantified using individual fluorescent images Table 1 ). The relative expression levels of SpCas9 was calculated using the ΔΔ Ct method with normalization to mCherry.
Statistical Analysis
All statistical analyses were performed using Prism 7 software (GraphPad Software, Inc., La Jolla, CA, USA). Group data are represented as mean ± SEM unless otherwise noted. Mean data were analyzed with unpaired t-tests, one-way or two-way analysis of variance (ANOVA) followed by post-hoc analysis (GraphPad Prism 7.0). A value of p < 0.05 was taken to be statistically significant.
RESULTS
Generation and validation of kamikaze CRISPR/Cas construct in vitro .
We first validated four sgRNAs (Figure 2A ) for SpCas9 targeting using an in situ cleavage assay.
Robust cleavage of the SpCas9 plasmid (pX551) was found when each of the four designed SpCas9 sgRNAs were introduced to recombinant SpCas9 protein ( Figure 2B) . 
Retinal function and structure assessment by electroretinography (ERG) and optical coherence tomography (OCT).
To evaluate the effect of our "kamikaze" CRISPR/Cas construct on retinal function and structure, ERG and OCT were performed at 8 weeks after intravitreal injection of viral suspensions in 
DISCUSSION
This study builds on our recent work using AAV2-mediated CRISPR/Cas to edit genes in mouse retina. While CRISPR/Cas9-mediated genome editing has shown promise for correcting disease-causing mutations, the potential for genotoxic effects with prolonged expression of CRISPR/Cas9 poses a significant barrier to the clinical utility of this technology. A recent study suggest that there can be an unexpectedly high number of single-nucleotide variants in mice that had undergone CRISPR/Cas9-mediated genome editing. 18 Several strategies have been employed in an attempt to avoid off-target cleavage, including improved guide RNA design, 19, 20 27 who demonstrated that progressively inactivating the nuclease using a Cas9 self-inactivating editing system resulted in a lower frequency of off-target cleavage in human iPSCs-derived neurons in vitro and in mouse brains in vivo . 27 This highlights the potential for a viral-mediated self-destructive CRISPR/Cas systems to be potentially used as a safer tool for in vivo genome editing.
We observed a reduction in the efficiency of SpCas9 gene perturbations with the kamikaze CRISPR/Cas system between in vitro (85.7%) and in vivo (63.8% at 8 weeks after injection;
supplementary Figure 5 ) models. This difference may be due to the different promoters and delivery systems used in vitro and in vivo . A constitutively ubiquitous cytomegalovirus (CMV) promoter was used to drive the expression of SpCas9 targeting sgRNA in the in vitro experiment, whereas the MeCP2 promoter was used to achieve specific neuronal expression in vivo . Lower in vivo efficiency may also explain why levels of SpCas9 protein in the mouse retina were undetectable by western blot analysis (Supplementary Figure 6) . Another difference was that a dual AAV2 vector system was employed to deliver the kamikaze CRISPR/Cas construct in vivo . We and others have recently demonstrated that CRISPR/Cas9 delivered using a dual AAV2 vector can effectively edit the genome in a number of organs in adult mice. 10, [28] [29] [30] However, expression of the CRISPR/Cas9 machinery requires the receipt of both Cas9 and sgRNA expression cassettes from two separate viral vectors, which may significantly reduce editing efficiency. 28 Although a single viral vector system employing Cas9 orthologs such as SaCas9 31 or CjCas9 32 may provide better in vivo editing efficiency, dual-vector systems may still be required for mutation correction as they enable delivery of donor templates and appropriate promoter elements. non-functional proteins resulting from on-target deletions (indel) may have a deleterious effect on retinal protein homeostasis. 34 Moreover, a recent study also indicated that large on-target deletions could lead to potential genotoxicity. 29 Whether such mechanisms account for the functional deficits observed in our study requires further investigation. Nevertheless these data highlight the need for careful design of AAV-CRISPR/Cas9 system for application in complex tissues.
In summary, we describe and characterise a self-destructive "kamikaze" CRISPR/Cas system for in vivo genome editing in the retina. This self-destructive kamikaze CRISPR/Cas system can effectively reduce the expression of SpCas9 in the mouse retina, without substantially sacrificing on-target editing efficiency. Therefore, our AAV2-mediated self-destructive CRISPR/Cas may be a robust tool for genome editing in the retina, especially when combined with high fidelity forms of CRISPR/Cas. Figure 1 . Schematics of Kamikaze CRISPR/Cas system. A dual AAV vector system was used. One viral vector was used to deliver SpCas9 and the other delivered sgRNAs against SpCas9 and the target locus ( YFP) , in the presence of mCherry . Statistical analysis between groups was performed using two-tailed Student's t-test. Asterisks denotes significance *P<0.05, **P<0.001, ***P<0.0001.
FIGURE LEGENDS
SUPPLEMENTARY METHODS AND RESULTS
Supplementary
